Elsevier

Gynecologic Oncology

Volume 158, Issue 3, September 2020, Pages 570-575
Gynecologic Oncology

Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract

https://doi.org/10.1016/j.ygyno.2020.05.682Get rights and content

Highlights

  • Single-agent pembrolizumab had minimal antitumor activity against small cell neuroendocrine tumors of the gynecologic tract.

  • Single-agent pembrolizumab had acceptable toxicity in patients with small cell neuroendocrine tumors of the gynecologic tract.

  • Primary small cell neuroendocrine tumors of the gynecologic tract were associated with low PD-L1 expression.

Abstract

Objective

To investigate the efficacy and safety of pembrolizumab in women with recurrent small cell neuroendocrine tumors of the lower genital tract.

Methods

We conducted an open-label, investigator-initiated phase II basket trial of pembrolizumab 200 mg intravenously every 3 weeks in patients with rare tumors (ClinicalTrials.gov: NCT02721732). The trial had prespecified cohorts, including small cell malignancies of extrapulmonary origin. Eligibility criteria included disease progression during standard treatment in the 6 months before study enrollment. Patients were enrolled from February 2017 to February 2019. The primary endpoint was the proportion of patients alive without progression at 27 weeks. Response to pembrolizumab was evaluated every 9 weeks (3 cycles) with radiographic imaging.

Results

Seven women with gynecologic extrapulmonary small cell carcinoma were enrolled, 6 with cervical and 1 with vulvar carcinoma. No patient was progression free at 27 weeks. At first radiologic assessment, 1 patient had stable disease, while 6 had progression. The single patient with stable disease at 6 weeks had disease progression at 14 weeks. The median progression-free interval was 2.1 months (range 0.8–3.3 months). Severe treatment-related adverse events (≥grade 3) were seen in 2 of 7 patients (29%); 1 patient had grade 3 asymptomatic elevation of serum alkaline phosphatase, and 1 had grade 3 asymptomatic elevation of serum alanine aminotransferase.

Conclusions

Pembrolizumab alone showed minimal activity in women with recurrent small cell neuroendocrine tumors of the lower genital tract. Treatment was well tolerated in the majority of study participants, and the rate of severe adverse events was low.

Introduction

High-grade neuroendocrine carcinomas of the cervix (small cell, large cell, and undifferentiated) account for <2% of all newly diagnosed cervical cancers. These tumors are highly aggressive and have high rates of recurrence. Even though >70% of women with high-grade neuroendocrine carcinoma of the cervix are diagnosed with early-stage disease, the 5-year survival rate for all patients with this disease is <30% [1]. Consensus guidelines detailing recommended therapies for newly diagnosed patients have been published, but none of these guidelines offer options for recurrent disease [2,3]. The National Comprehensive Cancer Network guidelines for treating cervical cancer specifically exclude high-grade neuroendocrine carcinoma [4]. Combination chemotherapy with topotecan, paclitaxel, and bevacizumab has emerged as a common regimen for recurrent small cell neuroendocrine carcinoma of the cervix but even with these drugs, median overall survival after first recurrence is <10 months [5]. There are very few active regimens for women with recurrent disease, and new treatment options are desperately needed.

Many therapeutic approaches for treating women with high-grade neuroendocrine carcinomas of the cervix have been extrapolated from studies in small cell lung cancer as the diseases appear histologically alike with similar clinical behavior. Studies have demonstrated the activity of single-agent checkpoint inhibitors in treating recurrent small cell lung cancer. The KEYNOTE-028 study reported an objective response rate of 33% (1 complete response, 7 partial responses) for the anti-PD-1 antibody pembrolizumab in 24 patients with recurrent small cell lung cancer [6]. The CheckMate-032 study also showed good activity for PD-1 inhibitors in recurrent small cell lung cancer: 10 (10%) of 98 patients had a partial response to single-agent nivolumab, and an additional 22 (22%) had stable disease [7].

Immune checkpoint inhibitors have also shown promise in the most common types of cervical cancer. Over 98% of cervical cancers are of squamous, adenocarcinoma, or adenosquamous histologies. In 98 patients with such tumors, pembrolizumab demonstrated an overall response rate of 12% (3 complete responses and 9 partial responses) [8]. Nivolumab as a single agent has been explored in 2 different studies in cervical cancer. In a study of 19 patients, the objective response rate was 26% (3 complete responses and 2 partial responses), and another 8 patients (42%) had stable disease [9]. Results of a second study, however, were less impressive: only 1 (4%) of 25 evaluable patients achieved a partial response (duration of response, 3.8 months), and another 9 (36%) had stable disease [10]. The median duration of response for those with stable disease was only 5.7 months.

Although there is a single case report of nivolumab as an active agent in a woman with recurrent high-grade neuroendocrine carcinoma of the cervix [11], we identified no prospective studies evaluating the activity of PD-1/PD-L1 inhibitors in high-grade neuroendocrine carcinomas of the cervix in a search of PubMed. As part of a multi-arm basket trial for patients with rare tumors, we evaluated the safety and clinical efficacy of pembrolizumab in a cohort of women with small cell neuroendocrine carcinomas of the lower genital tract.

Section snippets

Methods

This phase II, open-label study of single-agent pembrolizumab (ClinicalTrials.gov: NCT02721732) was approved by both the US Food and Drug Administration and the Institutional Review Board at The University of Texas MD Anderson Cancer Center. All patients were enrolled at MD Anderson Cancer Center. Patients with recurrent or advanced rare tumors were enrolled into one of 10 cohorts: 1) squamous cell carcinoma of the skin, 2) small cell malignancies of extrapulmonary origin, 3) adrenocortical

Results

Twelve patients with extrapulmonary small cell carcinoma were enrolled in this cohort between February 2017 and February 2019. Six patients had cervical cancer, 4 had prostate cancer, 1 had vulvar cancer, and 1 had small cell carcinoma of unknown primary. No patients in the cohort met the primary endpoint of nonprogression at 27 weeks, and therefore no further patients with extrapulmonary small cell carcinoma were enrolled.

Seven patients had a small cell carcinoma of gynecologic origin.

Discussion

Our group recently reported a phase II study of pembrolizumab in patients with rare tumors. Anti-tumor activity was observed in patients with adrenal cortical carcinoma, paraganglioma, squamous cell carcinoma of skin, and cancers of unknown origin [12]. However, in this phase II clinical trial, no patients with gynecologic small cell neuroendocrine carcinoma showed response to single-agent pembrolizumab. One patient had stable disease at her first assessment, at 6 weeks, but was noted to have

CRediT authorship contribution statement

Michael Frumovitz: Conceptualization, Resources, Project administration, Investigation, Formal analysis, Writing - original draft, Writing - review & editing. Shannon N. Westin: Resources, Project administration, Investigation, Writing - original draft, Writing - review & editing. Gloria Salvo: Project administration, Investigation, Writing - original draft, Writing - review & editing. Abdulrazzak Zarifa: Project administration, Investigation, Writing - original draft, Writing - review &

Declaration of competing interest

Dr. Frumovitz reports personal fees from Stryker, grants and non-financial support from Astra Zeneca, personal fees from Biom'Up, outside the submitted work.

Dr. Jazaeri reports personal fees from Iovance Advisory Board Meeting, Nuprobe, Simcere, Pact Pharma; grants from Astra Zeneca, BMS, Iovance, Aravive, Pfizer, Immatics USA, Eli Lilly, and non-financial support from Astra Zeneca, outside the submitted work.

Dr. Karp reports other from Phosplatin Pharmaceutical Co., personal fees from Black

Acknowledgments

Supported by Merck and the NIH/NCI under award number P30CA016672, which supports the MD Anderson Clinical Trials Office.

References (23)

  • W.J. Koh et al.

    Cervical Cancer, version 3.2019, NCCN clinical practice guidelines in oncology

    J. Natl. Compr. Cancer Netw.

    (2019)
  • Cited by (40)

    • High grade neuroendocrine carcinoma of the cervix

      2023, Diagnosis and Treatment of Rare Gynecologic Cancers
    • Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials

      2022, Cancer Treatment Reviews
      Citation Excerpt :

      Little guidance on optimal therapy exists and patients commonly receive radiotherapy-based treatment or radical surgery combined with neoadjuvant/adjuvant chemotherapy, with recurrence averaging 16 months after treatment and with a mean OS duration of 40 months [81,82]. Small exploratory studies and case reports in patients with previously treated neuroendocrine tumors exhibit positive results with nivolumab combinations or monotherapy [83–85] and with adoptive immune cell therapy [86], but not with pembrolizumab monotherapy [87]. Further studies of immunotherapy in these rare tumors are needed.

    View all citing articles on Scopus
    View full text